

Prof. Dr. med. Hermann Einsele



Kontakt:

E-Mail: einsele_h (at) ukw.de

Spamschutz: Bitte ersetzen Sie (at) durch @

C4 Professor for Internal Medicine
Chairman of the Department of Internal Medicine II,
University Hospital Würzburg, Germany
Vice Dean of the Faculty of Medicine, Julius-Maximilians-
University of Würzburg, Germany
President of the German Society for Hematology and
Medical Oncology

University Hospital Würzburg
Department of Internal Medicine II
Oberdürrbacher Str. 6
D-97080 Würzburg

Academic Degrees

- | | |
|------|--|
| 1996 | Board Examination in Hematology and Oncology, University of Tübingen |
| 1991 | Venia legendi for Internal Medicine |
| 1986 | MD thesis at the University of Tübingen, Institute for Experimental and Clinical Pharmacology and Toxicology, Tübingen |

Current Position(s)

- | | |
|------------|--|
| Since 2004 | Full Professor (C4) for Internal Medicine, Chairman of the Department of Internal Medicine II, University Hospital Würzburg, Germany |
| Since 2022 | Vice Dean of the Faculty of Medicine, Julius-Maximilians-University of Würzburg, Germany |
| Since 2022 | President of the German Society for Hematology and Oncology, Berlin, Germany |

Previous Positions

- | | |
|-------------|---|
| 2015 – 2021 | Vice President of the Julius-Maximilians-University Würzburg |
| 2011 – 2015 | Vice Dean of the Faculty of Medicine, Julius-Maximilians-University of Würzburg |
| 2003 | Visiting Professor, City of Hope Hospital, Duarte, USA |
| 2001 – 2004 | Head of the Allogeneic Stem Cell Transplantation Program, Tübingen, Germany |
| 2001 | Visiting Professor, City of Hope Hospital, Duarte, USA |
| 1999 | Visiting Professor, Fred Hutchinson Cancer Research Center, Seattle, USA |

| | |
|-------------|---|
| 1999 – 2004 | Associate Professor, Internal Medicine II, Eberhard Karls University, Tübingen, Germany |
| 1996 | Chair of the Deutsche Studiengruppe Multiple Myelom (DSMM) |
| 1993 – 1999 | Assistant Professor, Internal Medicine II, University of Tübingen, Germany |

Honors and Prizes

| | |
|------------|---|
| 2003 | Van Bekkum Award of the European Group for Blood and Marrow Transplantation |
| 2011 | Honory Fellow of the Royal College of Pathology, London |
| 2012 | Nobel Lecturer Stem cell Biology/Transplantation, Nobel Forum Karolinska Institute, Stockholm, Sweden |
| Since 2014 | Member of the Academy of Science and Literature, Mainz, Germany |
| Since 2017 | ISI: “Highly Cited Researcher” in the category Clinical Medicine |
| 2022 | Erasmus Hematology Award 2022 |
| 2022 | Bavarian Order of the Constitution |
| 2023 | Emil-von-Behring Prize |

Elevant Role in Scientific Societies/Networks

| | |
|-------------|---|
| Since 2022 | President of the German Society for Hematology & Oncology (DGHO) |
| Since 2022 | Vice Dean of the Faculty of Medicine, University of Würzburg |
| Since 2020 | Chair of the Scientific Advisory Board, Wilhelm Sander Stiftung |
| Since 2020 | Councilor to the Board of the European Hematology Association (EHA) |
| Since 2019 | Executive Member of the European Myeloma Network (EMN) |
| Since 2017 | Chairman of the Scientific Working Group “Immunotherapy”, European Hematology Association (EHA), Amsterdam |
| 2015 - 2021 | Vice President of the Julius-Maximilians University of Würzburg |
| Since 2015 | Member Scientific Advisory Board Faculty of Medicine, Friedrich Schiller University Jena |
| Since 2014 | Member of the grants committee for clinical studies of the DFG |
| 2014 – 2020 | Reviewer European Research Council (ERC), advanced grants, Brussels |
| 2012 – 2021 | Advisory board member in the funding program "Zwanzig20 - Partnership or Innovation" of the Federal Ministry of Education and Research (BMBF), Berlin |
| 2011 – 2015 | Vice Dean of the Faculty of Medicine, University of Würzburg |

Funded Research

European Commission FP6 Integrated Project “Allostem“, 2004–2008 (9.6 Mio €)

German Research Foundation (DFG) KFO/CRU 216 „Characterization of the Oncogenic Signaling Network in Multiple Myelom: Development of Targeted Therapies“, 2009–2016 (8.5 Mio €)

European Commission FP7 integrated Project “Nano II“, 2010–2013 (7.4 Mio €)

European Commission FP7 integrated Project “Optatio: Optimizing targets and therapeutics in high risk and refractory Multiple Myeloma“, 2012–2014 (4.3 Mio €)

German Research Foundation (DFG), Collaborative Research Center CRC/TRR 124, 2013–2025 (30.2 Mio €)

European Commission FP7 “T-Control: Donor T Cells for Immune Control“, 2013–2017 (7.4 Mio €)

Wilhelm Sander Foundation, Sander Therapy Unit: Multiple Myeloma, 2014–2017 (3 Mio €)

Federal Ministry of Education and Research (BMBF), Immunquant “Effect of antibody and T cell-based immunotherapies as a function of antigen density, 2017-2020 (Würzburg 1 Mio. €)

European Commission FP7 Horizon 2020, Project “EURE-CART: European Endeavour for Chimeric Antigen Receptor Therapies“, 2017–2021 (5.9 Mio €)

European Commission Horizon 2020, CARAMBA „SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma, 2018–2022 (6.1 Mio €)

German Research Foundation (DFG), Collaborative Research Center CRC/TRR 221, 2018–2025 (15.56 Mio €)

German Research Foundation (DFG), Research Group FOR 2830 since 2019 (2,8 Mio €)

European Myeloma Network, 2019–2027 (1 Mio. €)

Federal Ministry of Education and Research (BMBF), National Center for Tumor Diseases (NCT WERA), since 2020

German Research Foundation (DFG), Clinical research group 5001 2021–2024 (6.1 Mio €)

Federal Ministry of Education and Research (BMBF), "Imagine: Fighting Cancer with Optimal Personalized Immunotherapies", 2021 - 2024 (11,6 Mio €)

German Research Foundation, Collaborative Research Center CRC/TRR 338 „LETSIMMUN – Lymphocyte Engineering for Therapeutic Synthetic Immunity“, 2021–2025 (12 Mio €)